Angiogenic pathways in diabetic retinopathy

New England Journal of Medicine

Volumn 353, Issue 8, 2005, Pages 839-841

  Aiello, Lloyd Paul ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; METALLOPROTEINASE INHIBITOR; PEGAPTANIB; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; SOMATOMEDIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; ERYTHROPOIETIN; VASCULOTROPIN A;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG APPROVAL; EDITORIAL; GLUCOSE METABOLISM; HUMAN; LASER COAGULATION; NIGHT VISION; OXIDATIVE STRESS; PERIPHERAL VISION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RETINA BLOOD VESSEL OCCLUSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT; METABOLISM; NOTE; PATHOPHYSIOLOGY; RETINA;

DIABETIC RETINOPATHY; ERYTHROPOIETIN; HUMANS; RETINA; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23944480405     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058142     Document Type: Editorial

References (15)

1. World Health Organization. Magnitude and causes of visual impairment. (Accessed August 4, 2005, at http://www.who.int/mediacentre/factsheets/fs282/en/ .)
2. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care 1998;21:143-56.
3. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88.
4. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K 1948;68:137-80.
5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
6. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
7. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997;13:37-50.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
10. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53.
11. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003;195:241-8.
12. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707.
13. Singerman LJ, Macugen Diabetic Retinopathy Study Group. Findings of the phase 2 trial of the safety and efficacy of pegaptanib sodium (Macugen) I patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2005;46:E-4674. abstract (Web only). (Accessed August 4, 2005, at http://www.iovs.org/.)
14. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-92.
15. Becerra SP, Amaral J. Erythropoietin - an endogenous retinal survival factor. N Engl J Med 2002;347:1968-70.